ASH Annual Meeting and Exposition

ASH Annual Meeting and Exposition

Perspective from Julie Panepinto, MD, MSPH
December 08, 2014
2 min read

Luspatercept increased hemoglobin, decreased transfusion requirement in beta-thalassemia

Perspective from Julie Panepinto, MD, MSPH
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN FRANCISCO – The recombinant fusion protein luspatercept increased hemoglobin levels in patients with nontransfusion-dependent beta-thalassemia, according to study results presented at the ASH Annual Meeting and Exposition.

Luspatercept (ACE-536, Acceleron Pharma) — which contains a modified activin receptor type IIB linked to the Fc protein of human immunoglobulin 1 (IgG1) — also decreased the need for transfusion and serum ferritin levels in transfusion-dependent patients with beta-thalassemia, results showed.

“This compound has demonstrated an ability to correct anemia and improve the clinical condition of thalassemia in animal models,” Antonio G. Piga, MD, of the Azienda Ospedaliero-Universitaria San Luigi Gonzaga in Turin, Italy, said during a press briefing. “It has been tested in humans in phase 1 and now phase 2, and these results in beta-thalassemia are extremely exciting.”

The analysis included 23 patients who were nontransfusion dependent — or who had received fewer than 4 units of red blood cells 8 weeks prior to baseline — who had an 8.3-g/dL mean baseline hemoglobin level. The study also included an additional seven patients who were transfusion dependent, defined by the receipt of at least 4 units of red blood cells 8 weeks prior to baseline.

The median age of patients was 34.5 years (range, 20-57), 53% were male and 83% had previously undergone splenectomy.

All patients received subcutaneous luspatercept every 3 weeks for up to five doses in 0.2-mg/kg, 0.4-mg/kg, 0.6-mg/kg, 0.8-mg/kg or 1-mg/kg doses.

The primary endpoint was a ≥1.5 g/dL hemoglobin increase for at least 2 weeks for nontransfusion-dependent patients, and a transfusion burden reduction of ≥20% over 12 weeks for transfusion-dependent patients.

Researchers noted 75% of all patients who received 0.8-mg/kg or 1-mg/kg doses of luspatercept achieved the study’s primary endpoint.

All seven transfusion-dependent patients experienced a ˃60% reduction in their transfusion burdens.

Four of five transfusion-dependent patients with iron overload at baseline had a decrease in liver iron concentration ranging from 0.7 mg/g to 4.7 mg/g at 16 weeks. All five patients exhibited 12% to 60% reductions in serum ferritin levels from baseline.

Among nontransfusion-dependent patients, eight of 12 who had iron overload at baseline experienced ≥1 mg/g decreases in liver iron concentration by 16 weeks.

One transfusion-dependent and one nontransfusion-dependent patient each experienced the resolution of long-standing leg ulcers after 3 months of treatment, Piga said.

The most common adverse events associated with luspatercept were bone pain (20%), headache (17%), myalgia (13%) and asthenia (10%). Data showed there were no changes in platelet or white blood cells, and there were no serious adverse events.

“These are preliminary results and we are very excited to start a large phase 3 trial to [confirm them],” Piga said.

For more information:

Piga AG. Abstract #53. Presented at: ASH Annual Meeting and Exposition; Dec. 6-9, 2014; San Francisco.

Disclosure: The researchers report research funding and honoraria from; board of directors/advisory roles and employment with; and equity ownership in Acceleron Pharma, ApoPharma, Celgene and Novartis.